Gedea Biotech

Gedea Biotech developes pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge, in the absence of itching. Standard treatment consists of antimicrobials, but recurrence rate is15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health in 2021 and research into novel non-antimicrobial based treatments is timely.